Europe's Stocks Tumble Amid Ominous Oil Price Rise and Pharma Trial Failures
European markets declined on Tuesday as Brent crude prices approached the $100 mark amid escalating Middle Eastern geopolitical risks. The STOXX 600 index, a benchmark for European equity markets, fell 0.6% to approximately 646 points during morning trading hours.
Novartis, a pharmaceutical company based in Basel, Switzerland, suffered its steepest single-day decline in company history, plummeting more than 10% after consecutive failures in drug trials. The company's del-desiran candidate for treating myotonic dystrophy failed to achieve its primary clinical endpoint, and its investigational cholesterol therapy, pelacarsen, also fell short in late-phase clinical testing.
Meanwhile, Brent crude futures climbed approximately 2% following Iranian warnings of potential strikes on Gulf region energy facilities. Elevated crude prices are amplifying inflationary pressures throughout Europe and worldwide, prompting expectations that central banks will maintain elevated interest rates for an extended period.